Welcome to our dedicated page for bioAffinity Technologies Warrant news (Ticker: BIAFW), a resource for investors and traders seeking the latest updates and insights on bioAffinity Technologies Warrant stock.
bioAffinity Technologies, Inc. develops noninvasive diagnostic tests for lung cancer and other lung diseases, with recurring news centered on its CyPath® Lung sputum-based diagnostic. Company updates describe clinical case studies, physician education, pulmonary nodule management, commercialization of the test, and laboratory services provided through Precision Pathology Laboratory Services.
News also covers bioAffinity’s flow cytometry and automated analysis platform, including research directed at asthma and chronic obstructive pulmonary disease diagnostics. The company reports developments involving clinical studies, scientific presentations, test adoption, revenue trends, equity financings, and the use of CyPath® Lung as a Laboratory Developed Test under CLIA oversight.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.